SLC5A2 and obesity due to melanocortin 4 receptor deficiency: Since SGLT2 inhibitors seem to be an attractive therapeutic opportunity for metabolic liver disease management, these findings come in support of a beneficial effect for empagliflozin in the regulation of hepatic metabolism in a context of obesity and diabetes.